HOXA11 belongs to the AbdB homeobox gene family and regulates anterior-posterior patterning during embryogenesis. It is essential for uterine development, female fertility, and the cyclic remodeling of the endometrium . In cancer, HOXA11 overexpression promotes epithelial-mesenchymal transition (EMT), metastasis, and immune evasion . The antibody detects HOXA11 in human, mouse, and rat samples, making it a versatile tool for cross-species studies.
FITC is a green fluorescent dye with excitation/emission wavelengths of ~495/519 nm, ideal for co-localization studies with red-fluorescent markers. The conjugation enhances the antibody’s utility in:
Immunofluorescence (IF): Visualizing HOXA11 in subcellular compartments (e.g., nucleus, cytoplasm).
Fluorescence-Activated Cell Sorting (FACS): Quantifying HOXA11-expressing cell populations.
Immunocytochemistry (ICC): Mapping protein expression in tissue sections.
The FITC-conjugated antibody is used to track HOXA11’s dynamic expression in developmental and disease contexts:
Embryogenesis: Visualizing HOXA11 in the developing uterus and limb buds to study morphogenesis .
Cancer: Detecting HOXA11 in gastric carcinoma (GC) cells to assess its role in peritoneal metastasis . In co-culture models, HOXA11-overexpressing GC cells induce mesothelial fibrosis, which the antibody helps quantify via IF .
HOXA11 interacts with signaling pathways (e.g., PDGF BB/TGF-β1) to drive fibrosis and immune evasion. For example:
Immune Escape: HOXA11 upregulates PD-L1 via FOSL1 and PTBP1, enabling tumor evasion of CD8+ T cells. The antibody aids in correlating HOXA11 expression with PD-L1 levels in hypopharyngeal squamous cell carcinoma (HSCC) .
Metastasis: HOXA11 promotes EMT and anoikis resistance in GC cells, as demonstrated by IF-based studies .